Navigation Links
Hybrid Fuels, Inc. Announces FDA Approved Lab Selection for Azul Instant™ - "Be Ready in an Instant"
Date:2/2/2012

FORT LAUDERDALE, Fla., Feb. 2, 2012 /PRNewswire/ -- Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that after a lengthy and heavily scrutinized review process that it has selected a state-of-the-art FDA approved laboratory to manufacture all new orders of Azul Instant™.

The laboratory was chosen based on its compliance standards and ability to ramp capacity quickly due to the increasing demand for the Azul Instant™ product in the market.  The laboratory is a cGMP (current good manufacturing practice) compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals.  Azul Instant™ will be manufactured in the USA. 

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals.  The formula was developed with the same principals as other erectile dysfunction pharmaceuticals but in a safe and natural formulation.  Patients will now receive the NATURAL benefits of Azul Instant™ without experiencing the side effects associated with prescription medications. While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works within 5 minutes.  Azul Instant™ lasts for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects.

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc., the Company's pending name change.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:
Hybrid Fuels, Inc. - 954-903-2993


'/>"/>
SOURCE Hybrid Fuels, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
2. Philips and ACC Address the Growing Demand for Minimally Invasive Cardiology Interventions by Showcasing Hybrid OR Solutions at ACC 2010
3. Frost & Sullivan Award Highlights Hybridyne Technologies Outstanding Technology Innovation
4. Cardicas Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
5. MetroSouth Surgeon Pioneers Hybrid Treatment of Large Hiatal Hernias and Reflux
6. Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry
7. Hybrid Fuels, Inc. Announces New Business Strategy
8. Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems
9. Synteract Releases SynCapture Version 1.5 of Its Hybrid Electronic Data Capture (EDC) System
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):